A novel orf virus vector-based COVID-19 booster vaccine shows cross-neutralizing activity in the absence of anti-vector neutralizing immunity

• Main Authors: Ute Klinkhardt (Author), Mirjam Schunk (Author), John Ervin (Author), Christoph Schindler (Author), Danny Sugimoto (Author), Bruce Rankin (Author), Ralf Amann (Author), Martina Monti (Author), Anna Kutschenko (Author), Carsten Schumacher (Author), Kristina Huber (Author), Andreas Zeder (Author), Nelli Heikkila (Author), Arnaud M. Didierlaurent (Author), Sylvia E. Schwarz (Author), Madiha Derouazi (Author)
• Format: Book
• Published: Taylor & Francis Group, 2024-12-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Next-generation COVID-19 vaccines are being developed to expand the breadth of coverage against existing and future variants and to extend the duration of protection. Prime-2-CoV_Beta is an orf virus (ORFV) based multi-antigen COVID-19 vaccine that co-expresses Spike (S) and Nucleocapsid (N) antigen...